Beschreibung
Gene therapy has expanded rapidly over the last decade. The number of clinical trials reported by 2001 included 532 protocols and 3436 patients. Phase I trials predominate with 359 trials of 1774 patients versus Phase II (57 trials with 507 patients) and Phase III (3 trials of 251 patients). The disease overwhelmingly targeted by gene therapy is cancer: involving 331 trials with 2361 patients. Despite the somewhat disappointing results of clinical trials to date, gene therapy offers tremendous promise for the future of cancer therapy. The area of gene therapy is vast, and both malignant and nonmalignant cells can be targeted. Suicide Gene Therapy: Methods and Reviews covers gene therapy that targets malignant cells in a treatment that has become known as "suicide gene therapy. " Basically, this approach uses the transduction of cancer cells with a gene for a foreign enzyme that, when expressed, is able to activate a nontoxic prodrug into a highly cytotoxic drug able to kill the cancer cell population. This is a major area in cancer gene therapy-in 2001 this technique was represented by 52 clinical protocols with a total of 567 patients. Additional trials used multiple gene therapy protocols that also involved suicide gene therapy (83 with 497 patients), indicating that the interest in this area is considerable. Suicide Gene Therapy: Methods and Reviews aims to cover comprehensively, both in theoretical and practical terms, the rapidly evolving area of suicide gene therapy for cancer.
Inhaltsverzeichnis
Introduction to the Background, Principles, and State of the Art in Suicide Gene Therapy Ion Niculescu-Duvaz and Caroline J. Springer Introduction to Vectors for Suicide Gene Therapy Caroline J. Springer Construction of VNP20009: A Novel, Genetically Stable Antibiotic-Sensitive Strain of Tumor-Targeting Salmonella for Parenteral Administration in Humans Kenneth Brooks Low, Martina Ittensohn, Xiang Luo, Li-Mou Zheng, Ivan King, John M. Pawelek, and David Bermudes Nonreplicating DNA Viral Vectors for Suicide Gene Therapy: The Adenoviral Vectors Masato Yamamoto and David T. Curiel Replication-Selective Oncolytic Adenoviruses Gunnel Hallden, Stephen H. Thorne, Jingping Yang, and David H. Kirn Retroviral Vectors for Suicide Gene Therapy Colin Porter Nonviral Liposomes Andrew D. Miller Peptide- and Polymer-Based Gene Delivery Vehicles Richard Brokx and Jean Gariepy Design of Prodrugs for Suicide Gene Therapy Dan Niculescu-Duvaz, Ion Niculescu-Duvaz, and Caroline J. Springer Cytochrome P450-Based Gene Therapies for Cancer E. Antonio Chiocca and David J. Waxman Tumor Sensitization to Purine Analogs by E. coli PNP Kimberly V. Curlee, William B. Parker, and Eric J. Sorscher Enzyme-Prodrug Systems: Carboxylesterase/CPT-11 Mary K. Danks and Philip M. Potter Enzyme-Prodrug Systems: Thymidine Phosphorylase/5''-Deoxy-5-Fluorouridine Alexandre Evrard, Joseph Ciccolini, Pierre Cuq, and Jean-Paul Cano Methods to Improve Efficacy in Suicide Gene Therapy Approaches: Targeting Prodrug-Activating Enzymes Carboxypeptidase G2 and Nitroreductase to Different Subcellular Compartments Silke Schepelmann, Robert Spooner, Frank Friedlos, and Richard Marais Extracellular b-Glucuronidase for Gene-Directed Enzyme-Prodrug Therapy Sabine Brüsselbach Enhancement of Suicide Gene Prodrug Activation by Random Mutagenesis Jean-Emmanuel Kurtz and Margaret E. Black Combination Suicide Gene Therapy Wolfgang Uckert, Brian Salmons, Christian Beltinger, Walter H. Günzburg, and Thomas Kammertöns Immune Response to Suicide Gene Therapy Shigeki Kuriyama, Hirohisa Tsujinoue, and Hitoshi Yoshiji Targeting Cancer With Gene Therapy Using Hypoxia as a Stimulus Gabi U. Dachs, Olga Greco, and Gillian M. Tozer Radiation-Activated Antitumor Vectors Simon D. Scott and Brian Marples In Vitro and In Vivo Models for the Evaluation of GDEPT: Quantifying Bystander Killing in Cell Cultures and Tumors William R. Wilson, Susan M. Pullen, Alison Hogg, Stephen M. Hobbs, Frederik B. Pruijn, and Kevin O. Hicks Suicide Gene Therapy in Liver Tumors Long R. Jiao, Roman Havlik, Joanna Nicholls, Steen Lindkaer Jensen, and Nagy A. Habib Clinical Trials With GDEPT: Cytosine Deaminase and 5-Fluorocytosine Nicola L. Brown and Nicholas R. Lemoine The Nitroreductase/CB1954 Enzyme-Prodrug System Nicola K. Green, David J. Kerr, Vivien Mautner, Peter A. Harris, and Peter F. Searle Side Effects of Suicide Gene Therapy Marjolijn M. van der Eb, Bertie de Leeuw, Alex J. van der Eb, and Rob C. Hoeben Antibody-Directed Enzyme-Prodrug Therapy R. Barbara Pedley, Surinder K. Sharma, Robert E. Hawkins, and Kerry A. Chester Bioreductive Prodrugs for Cancer Therapy Beatrice Seddon, Lloyd R. Kelland, and Paul Workman Index
